A familial Alzheimer's genetic panel for adults over 65 sequences three genes — PSEN1, PSEN2, and APP — looking for a single mutation known to cause early-onset Alzheimer's disease. It finds a causative variant in roughly 60 to 80% of families with a clear history of early-onset disease, but ARUP Laboratories' test directory notes that clinical sensitivity drops sharply as the age of onset rises, so the panel catches far fewer causes in people who develop symptoms later in life.
That timing mismatch matters for anyone over 65 considering the test. The panel was built to explain Alzheimer's that strikes in someone's 30s, 40s, or 50s, not the much more common disease that appears after 65. A person in that older group who takes the panel is testing for a cause that, by definition, usually isn't theirs.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Three-Gene Panel Actually Finds
- Why a Negative Result Doesn't Mean "No Risk"
- What the Panel Misses — APOE4 and Late-Onset Risk
- Why Major Guidelines Discourage Routine Testing
- Who Should Actually Consider This Panel
- The Role of Genetic Counseling Before Any Test
- Frequently Asked Questions
What the Three-Gene Panel Actually Finds
PSEN1, PSEN2, and APP are the three genes definitively linked to autosomal-dominant Alzheimer's disease — meaning a single inherited mutation in any one of them is enough to cause the disease, typically decades before age 65. Among families where a causative mutation is identified, ARUP estimates PSEN1 accounts for roughly 20 to 70% of cases, APP for 10 to 15%, and PSEN2 for about 5%, according to ARUP Laboratories. The three genes also differ in when they typically strike.
PSEN1 and APP mutations usually produce symptoms in a person's 30s or 40s, while PSEN2-linked disease tends to start later, in the 50s or 60s, per the same ARUP data. None of the three is associated with a typical onset after 65. This is why the panel is designed around family history, not age. It exists to answer a specific question — does this family carry one of three known mutations that explain a pattern of early-onset dementia across generations — rather than to assess an individual's general risk of developing Alzheimer's late in life.
Why a Negative Result Doesn't Mean "No Risk"
A negative result on the PSEN1/PSEN2/APP panel does not rule out a heritable form of Alzheimer's. ARUP's own test documentation states that other causative genes may exist and remain unidentified or simply untested by this panel.
A clean result closes off three specific explanations; it does not close the book on genetics altogether. For someone over 65, this gap is especially wide. The panel wasn't built to explain late-onset disease in the first place, so a negative result mostly confirms that a rare early-onset mutation isn't present — information that, for most people in this age group, was unlikely to apply to them regardless.
What the Panel Misses — APOE4 and Late-Onset Risk
The gene most relevant to Alzheimer's risk after 65 isn't on this panel at all. APOE4 is a common gene variant, not a rare mutation, and it is the strongest known genetic risk factor for the late-onset form of the disease that affects the vast majority of people diagnosed after 65. A 2024 study in Nature Medicine, led by Fortea and colleagues and drawing on data from more than 13,000 people across the NACC database and five other cohorts, found that by age 65, nearly all people who inherited two copies of APOE4 — about 2 to 3% of the population — already had abnormal amyloid levels in their cerebrospinal fluid, and 75% had a positive amyloid PET scan.
Those same APOE4 homozygotes developed Alzheimer's symptoms at a median age of 65.1, within a narrower predicted age range than people with two copies of the more common APOE3 variant. The findings led the study's authors to argue that APOE4 homozygosity should be treated as its own genetic form of Alzheimer's disease, warranting its own prevention strategies, clinical trials, and treatment approach, according to the Nature Medicine study. That makes APOE status far more relevant to a typical reader over 65 than the three-gene familial panel — yet APOE is a separate test, ordered and interpreted differently, and is not part of the familial early-onset panel at all.
Why Major Guidelines Discourage Routine Testing
The Alzheimer's Association advises against routine genetic testing for Alzheimer's or dementia risk in healthy people — including APOE testing — until the person has received genetic counseling. The organization states that risk-estimating genetic tests currently hold value mainly in research or clinical-trial settings, not for predicting an individual's personal risk, according to the Alzheimer's Association.
A National Institute on Aging/Alzheimer's Association working group reached a similar conclusion specifically about APOE: a consensus statement published in The Lancet found that APOE genotyping's usefulness for predicting Alzheimer's risk in people without symptoms has not been established in longitudinal population studies, and the group does not recommend it for that purpose. Insurers apply a comparable standard to the familial panel itself. Commercial medical policies effective in 2026, including those from the Federal Employee Program (FEP Blue) and Excellus BCBS, consider targeted single-variant testing for a known familial PSEN1, PSEN2, or APP mutation medically necessary in someone without symptoms only when specific family-history criteria are met — not as routine screening for people over 65, according to FEP Blue's medical policy.
Who Should Actually Consider This Panel
The panel's intended use is narrow and specific. It makes sense for someone with a family history that looks like autosomal-dominant disease: For a person over 65 with no such family pattern, the test is unlikely to explain anything about their own risk, since the diseases it screens for almost always announce themselves decades earlier.
- Alzheimer's symptoms appearing in multiple generations before age 65, often in the 30s to 50s
- A parent or sibling already confirmed to carry a PSEN1, PSEN2, or APP mutation
- A pattern consistent with inheritance from one parent to roughly half of their children
The Role of Genetic Counseling Before Any Test
Because results — positive or negative, on either the familial panel or an APOE test — carry psychological and practical weight, the Alzheimer's Association and the National Society of Genetic Counselors caution against direct-to-consumer genetic testing for Alzheimer's risk without professional genetic counseling. Results interpreted without guidance can cause lasting psychological distress or raise insurance and employment concerns if mishandled. That concern isn't theoretical.
The randomized REVEAL trial found that disclosing APOE4 carrier status caused a short-term rise in anxiety and distress among recipients. The effects were generally not long-lasting, which supports counseling-supported disclosure as the safer path rather than ordering a direct-to-consumer kit alone. A genetic counselor can also determine, before any blood is drawn, whether a person's family history actually fits the pattern this panel is designed to catch.
Frequently Asked Questions
Does a negative result on this panel mean I won't get Alzheimer's?
No. It only rules out mutations in PSEN1, PSEN2, and APP; other genetic and non-genetic risk factors, including APOE4, are not covered by this panel.
Should someone over 65 get APOE testing instead?
APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's, but the Alzheimer's Association and an NIA/Alzheimer's Association working group both advise against routine APOE testing for individual risk prediction outside of research settings, and recommend genetic counseling before testing.
Will insurance cover the familial panel for someone over 65 with no early-onset family history?
Medical policies such as FEP Blue's 2026 policy generally require specific family-history criteria to be met before covering targeted PSEN1, PSEN2, or APP testing; routine testing without that history typically isn't covered.
